VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Increase in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totalling 58,200 shares, a growth of 75.8% from the September 15th total of 33,100 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 43,200 shares, the short-interest ratio is currently 1.3 days.

Institutional Trading of VYNE Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYNE. Lynx1 Capital Management LP purchased a new stake in VYNE Therapeutics in the 2nd quarter worth approximately $32,000. Virtu Financial LLC acquired a new stake in shares of VYNE Therapeutics during the first quarter worth $50,000. Parkman Healthcare Partners LLC purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $1,623,000. Finally, Eventide Asset Management LLC acquired a new position in VYNE Therapeutics in the fourth quarter valued at $3,249,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a research note on Thursday, September 12th.

VYNE Therapeutics Trading Up 3.8 %

Shares of VYNE stock traded up $0.07 during trading hours on Friday, hitting $1.91. The company’s stock had a trading volume of 40,786 shares, compared to its average volume of 76,643. The business has a fifty day moving average of $1.84 and a 200-day moving average of $2.19. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.48. The stock has a market cap of $28.17 million, a price-to-earnings ratio of -0.74 and a beta of 1.40.

VYNE Therapeutics (NASDAQ:VYNE) last announced its earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.11 million. VYNE Therapeutics had a negative net margin of 5,849.18% and a negative return on equity of 43.11%. On average, equities analysts expect that VYNE Therapeutics will post -0.86 EPS for the current fiscal year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.